Economic impact with home delivery of chemotherapy to pediatric oncology patients

• Published in: The Annals of pharmacotherapy Vol. 31; no. 2; p. 140
• Main Authors: Holdsworth, M T, Raisch, D W, Chavez, C M, Duncan, M H, Parasuraman, T V, Cox, F M
• Format: Journal Article
• Language: English
• Published: United States 01.02.1997
• Subjects: Adolescent; Antiemetics - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - economics; Child; Child, Preschool; Cost Savings; Evaluation Studies as Topic; Female; Home Care Services; Home Infusion Therapy - economics; Humans; Male; Nausea - chemically induced; Nausea - drug therapy; Neoplasms - drug therapy; United States; Vomiting - chemically induced; Vomiting - drug therapy; United States
• ISSN: 1060-0280
• DOI: 10.1177/106002809703100201

To examine the economic impact of a home chemotherapy program (HCP) for pediatric oncology patients. Factors that led to initiation of an HCP included availability of specially trained nurses and programmable ambulatory infusion devices at local home care agencies, routine central venous catheter placement, inpatient bed space shortages, and the availability of ondansetron. Chemotherapy delivery in the home setting from June 1991 through June 1994. Charge data and nausea and vomiting severity data were collected for patients treated through the HCP. Economic impact was calculated by incorporating and summing all charge categories associated with hospital admission for chemotherapy (HAC) versus delivery by the HCP. All data were adjusted for 1993 dollars, and reflect changes for the average patient size (1 m2). Charge data for each chemotherapy protocol delivered in the home were analyzed by calculating the differences between HAC and HCP charges using the following formula: charge difference (HAC - HCP) per protocol times the number of courses. Total economic impact was calculated by summing the differences in charges for each protocol. A total of 262 chemotherapy courses were given to 44 patients (mean age 9.5 +/- 5.1 y) through the HCP, which represented 1012 patient care days and 24 different chemotherapy protocols. Monetary savings from the HCP ranged from $5180 per course of ifosfamide plus etoposide to $367 per course for high-dose methotrexate. Total monetary savings from the HCP during the 3-year period was $640,793. Successful control of nausea and vomiting with a combination of ondansetron plus methylprednisolone was achieved in approximately 80% of the patients receiving highly emetogenic chemotherapy protocols. HCP for pediatric oncology patients results in substantial monetary savings to payors. Effective control of nausea and vomiting can be accomplished at home in the majority of patients with an ondansetron-based antiemetic regimen.